Cannapharmarx, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CPMD OTC Markets Indicat
• $27,009,769 — deficiency as of September 30, 2025, of $27,009,769, which has increased since the end of t
• $10,762,898 — bstantial related party debt, totalling $10,762,898 as of September 30, 2025, with accrued
• $3,248,127 — mber 30, 2025, with accrued interest of $3,248,127, which represents a significant portion

Filing Documents

• canna_8k.htm (8-K) — 33KB
• 0001654954-25-014070.txt ( ) — 147KB
• canna-20251212.xsd (EX-101.SCH) — 5KB
• canna-20251212_lab.xml (EX-101.LAB) — 14KB
• canna-20251212_cal.xml (EX-101.CAL) — 1KB
• canna-20251212_pre.xml (EX-101.PRE) — 9KB
• canna-20251212_def.xml (EX-101.DEF) — 2KB
• canna_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. CannaPharmaRX, Inc. (the "Company") announced today that the failure-to-file cease trade order (the "CTO") issued by the BC Securities Commission (the "BCSC") has been revoked effective December 12, 2025. The CTO was issued by the BCSC on May 11, 2023, as a result of its failure to file its annual audited financial statements for the year ended December 31, 2022; management's discussion and analysis for the year ended December 31, 2022; annual information form for the year ended December 31, 2022; and certificate of annual filings for the year ended December 31, 2022 (the "Delinquent Filings") as required under Canadian National Instrument 51-102 - Continuous Disclosure Obligations . The Company filed the Delinquent Filings on SEDAR and with the United States Securities and Exchange Commission (the "SEC"), making the last Delinquent Filing on October 19, 2023. Financial Condition and Risks Notwithstanding the revocation of the CTO, the Company continues to face risks and financial challenges in the short and long term including: substantial doubt exists about the Company's ability to continue as a going concern; the Company had a working capital deficiency as of September 30, 2025, of $27,009,769, which has increased since the end of the most recently completed financial year; and the Company has incurred substantial related party debt, totalling $10,762,898 as of September 30, 2025, with accrued interest of $3,248,127, which represents a significant portion of the Company's liabilities. Business Plan To address these challenges, in addition to obtaining the revocation of the CTO, among other things, the Company has developed a strategic plan to reduce long-term debt, strengthen the Company's financial position and to keep current in its short-term obligations. This strategic plan includes: negotiating with creditors, including related parties, to restructure and settle outstanding debt obligations; exploring opportunities to secur

Forward-Looking Statements

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", "plans" or "intends". Forward-looking statements contained in this release include, but are not limited to, statements or information with respect to: reinstatement of trading on the OTC Pink Sheets, the Company's ability to continue as a going concern, the Company's plans in European markets, and the Company's strategic plan, including the timing and execution thereof. Such statements are based on assumptions and address future events and conditions, by their very nature they involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents we file from time to time with the SEC and SEDAR+. There can be no assurance that such statements will prove to be accurate, as actual results and futu

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. The Revocation Order is being attached as an exhibit herewith. Exhibit No. Description 1.1 Revocation Order 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CANNAPHARMARX, INC. December 17, 2025 By: /s/ Constantine Nkafu Name: Constantine Nkafu Title: CEO 4

View Full Filing

View this 8-K filing on SEC EDGAR